LITESPARK-005: HRQoL with belzutifan versus everolimus for advanced RCC

3 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
In this latest episode of the VJOncoAlert Journal Club, Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK, and Brian Rini, MD, FASCO, Vanderbilt-Ingram Cancer Center, Nashville, TN, comment on the health-related quality of life (HRQoL) results of the LITESPARK-005 trial (NCT04195750) in advanced renal cell carcinoma (RCC), highlighting the benefits of belzutifan over everolimus in terms of toxicity and quality of life. The quality of life data supports the clinical efficacy of belzutifan, which is well-tolerated despite some adverse effects such as anemia and hypoxia. Further exploration of quality-of-life questionnaires and methods, particularly in the adjuvant setting, as well as the use of wearable devices and real-time patient data collection, can improve the accuracy of HRQoL assessments.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Category
Oncology
Be the first to comment

Up Next